Podcasts > Archived Podcasts > Industry Focus
This show is no longer producing new episodes. Check out our other shows.
Industry Focus
Healthcare: A Breach of Trust? Why The FDA's Taking Aim At Novartis' AveXis
Aug 14, 2019 (24:14)
The FDA is investigating Novartis' subsidiary AveXis because AveXis may have manipulated data on Zolgensma, a gene therapy with a sky-high price tag and blockbuster potential. Here's what could happen next. Also, Exact Sciences goes all in on cancer diagnostics. Why the Cologuard-maker is spending $2.7 billion in a push deeper into genetic testing.
Check out more of our content here:
- https://www.fool.com/podcasts/?utm_source=podcasts&utm_medium=podcasts&utm_campaign=industryfocus" rel="noopener" target="_blank">TMF's podcast portal
- https://www.youtube.com/user/TheMotleyFool" rel="noopener" target="_blank">YouTube
- https://twitter.com/mfindustryfocus?lang=en" rel="noopener" target="_blank">Twitter
- https://m.facebook.com/groups/217114601988296">Join Our Motley Fool Podcast Facebook Group
- https://www.linkedin.com/company/the-motley-fool">LinkedIn
- https://www.fool.com/ecap/the_motley_fool/stock-up/?aid=9205&source=isusitsz0000002&ftm_cam=stockup&ftm_veh=sidebarhelp&ftm_mes=signup"> StockUp, The Motley Fool's weekly email newsletter
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.